Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near‐infrared light mediated cancer therapy

Prasad, Rajendra; Jain, Nishant Kumar; Yadav, Amit Singh; Chauhan, Deepak S.; Devrukhkar, Janhavi; Kumawat, Mukesh Kumar; Shinde, Shweta; Gorain, Mahadeo; Thakor, Avnesh S.; Kundu, Gopal C.; Conde, João; Srivastava, Rohit

doi:10.1038/s42003-020-1016-z

Cited by 52 publications

(55 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite significant progress in the development of MRI-targeted nanotheranostic platforms and its undeniable potential in predictive, preventive, and personalized medicine, gaps in knowledge continue to hinder translation from bench to bedside and few nanotheranostic systems have undergone clinical trials. This can be due to several factors, including the complexity of the developed hybrid nanosystems; difficulty in predicting their complex effects and interactions with biological systems; species-dependent immune responses and toxicity profiles; difficulty in controlling the pharmacokinetic and biodistribution properties; premature release of the therapeutic cargo in blood and healthy tissue; toxicity concerns; and the significant differences between animal models and human cancer patients 191 - 193 . To improve success rates, recent research has focused on using imaging data to better understand the interactions between nanoparticles and biological systems to optimize tumor targeting and biodistribution.…”

Section: Discussionmentioning

confidence: 99%

“…This is especially true when a single agent can provide several functionalities including imaging and combinatorial therapy, such as combining chemotherapy with gene therapy or immunotherapy. An “all in one” nanotheranostic platform, however, requires a complex synthesis route and often shows a premature release of cargo, which can result in severe side effects 193 . In the end, clinical translation hinges on proving enhanced efficacy over existing therapies and demonstrating sufficient biocompatibility 196 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MRI-traceable theranostic nanoparticles for targeted cancer treatment

Anani¹,

Rahmati²,

Nayer³

et al. 2021

Theranostics

View full text Add to dashboard Cite

Current cancer therapies, including chemotherapy and radiotherapy, are imprecise, non-specific, and are often administered at high dosages - resulting in side effects that severely impact the patient's overall well-being. A variety of multifunctional, cancer-targeted nanotheranostic systems that integrate therapy, imaging, and tumor targeting functionalities in a single platform have been developed to overcome the shortcomings of traditional drugs. Among the imaging modalities used, magnetic resonance imaging (MRI) provides high resolution imaging of structures deep within the body and, in combination with other imaging modalities, provides complementary diagnostic information for more accurate identification of tumor characteristics and precise guidance of anti-cancer therapy. This review article presents a comprehensive assessment of nanotheranostic systems that combine MRI-based imaging (T1 MRI, T2 MRI, and multimodal imaging) with therapy (chemo-, thermal-, gene- and combination therapy), connecting a range of topics including hybrid treatment options ( e.g. combined chemo-gene therapy), unique MRI-based imaging ( e.g. combined T1-T2 imaging, triple and quadruple multimodal imaging), novel targeting strategies ( e.g. dual magnetic-active targeting and nanoparticles carrying multiple ligands), and tumor microenvironment-responsive drug release ( e.g. redox and pH-responsive nanomaterials). With a special focus on systems that have been tested in vivo , this review is an essential summary of the most advanced developments in this rapidly evolving field.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

MRI-traceable theranostic nanoparticles for targeted cancer treatment

Anani¹,

Rahmati²,

Nayer³

et al. 2021

Theranostics

View full text Add to dashboard Cite

show abstract

“…Contrary, nuclear techniques benefit from whole body capabilities, quantification, high sensitivity, and absence of tissue penetration issues, but presents limited spatial resolution [68]. For nuclear techniques, radiolabeling of liposomes was widely described in the literature [13,[69][70][71] with the use of several different labeling methods [72]. According to Man et al [68], in 2019, Tc-99m was the most commonly used radionuclide for liposome labeling.…”

Section: Medical Imagingmentioning

confidence: 99%

The Combination of Liposomes and Metallic Nanoparticles as Multifunctional Nanostructures in the Therapy and Medical Imaging—A Review

Musielak

Potoczny

Boś-Liedke

et al. 2021

IJMS

View full text Add to dashboard Cite

Nanotechnology has introduced a new quality and has definitely developed the possibilities of treating and diagnosing various diseases. One of the scientists’ interests is liposomes and metallic nanoparticles (LipoMNPs)—the combination of which has introduced new properties and applications. However, the field of creating hybrid nanostructures consisting of liposomes and metallic nanoparticles is relatively little understood. The purpose of this review was to compile the latest reports in the field of treatment and medical imaging using of LipoMNPs. The authors focused on presenting this issue in the direction of improving the used conventional treatment and imaging methods. Most of all, the nature of bio-interactions between nanostructures and cells is not sufficiently taken into account. As a result, overcoming the existing limitations in the implementation of such solutions in the clinic is difficult. We concluded that hybrid nanostructures are used in a very wide range, especially in the treatment of cancer and magnetic resonance imaging. There were also solutions that combine treatments with simultaneous imaging, creating a theragnostic approach. In the future, researchers should focus on the description of the biological interactions and the long-term effects of the nanostructures to use LipoMNPs in the treatment of patients.

show abstract

“…Considering the drawbacks of conventional therapies, NP-based drug delivery is a useful toolkit particularly for site-specific drug delivery, improved drug accumulation in tumor site due to the enhanced permeability and retention (EPR) effect, and the capability to bypass the MDR effects of the breast cancer cell [15][16][17][18]. In modern therapy, NPs can be further modified by equipping contrast agents, termed as theranostics for cancer diagnosis and treatment simultaneously [19]. In this review, we discuss different approaches to the targeted delivery of nanotherapeutics to cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

2021

View full text Add to dashboard Cite

The journey of chemotherapeutic drugs from the site of administration to the site of action is confronted by several factors including low bioavailability, uneven distribution in major organs, limited accessibility of drug molecules to the distant tumor tissues, and lower therapeutic indexes. These unavoidable features of classical chemotherapeutics necessitate an additional high, repetitive dose of drugs to obtain maximum therapeutic responses with the result of unintended adverse side effects. An erratic tumor microenvironment, notable drawbacks of conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells warrant precisely designed therapeutics for the treatment of cancers. In recent decades, nanoparticles have been deployed for the delivery of standard anticancer drugs to maximize the therapeutic potency while minimizing the adverse effects to increase the quality and span of life. Several organic and inorganic nanoplatforms that have been designed exploiting the distinctive features of the tumor microenvironment and tumor cells offer favorable physicochemical properties and pharmacokinetic profiles of a parent drug, with delivery of higher amounts of the drug to the pathological site and its controlled release, thereby improving the balance between its efficacy and toxicity. Advances to this front have included design and construction of targeted nanoparticles by conjugating homing devices like peptide, ligand, and Fab on the surface of nanomaterials to navigate nanoparticledrug complexes towards the target tumor cell with minimal destruction of healthy cells. Furthermore, actively targeting nanoparticles can facilitate the delivery and cellular uptake of nanoparticle-loaded drug constructs via binding with specific receptors expressed aberrantly on the surface of a tumor cell. Herein, we present an overview of the principle of targeted delivery approaches, exploiting drug-nanoparticle conjugates with multiple targeting moieties to target specific receptors of breast cancer cells and highlighting therapeutic evaluation in preclinical studies. We conclude that an understanding of the translational gap and challenges would show the possible future directions to foster the development of novel targeted nanotherapeutics.

show abstract

Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near‐infrared light mediated cancer therapy

Cited by 52 publications

References 56 publications

MRI-traceable theranostic nanoparticles for targeted cancer treatment

MRI-traceable theranostic nanoparticles for targeted cancer treatment

The Combination of Liposomes and Metallic Nanoparticles as Multifunctional Nanostructures in the Therapy and Medical Imaging—A Review

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

Contact Info

Product

Resources

About